Skip to main content
Equibles
EDIT logo

EDIT · Editas Medicine, Inc. · Metrics

Track EDIT — free

Use EDIT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EDIT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.57 -0.01 (-0.39%)
Russell 2000 member Rebalance outlook locked
Market Cap
$396.24M
Shares
153.58M
Volume · Oct 21 466.23K Avg daily vol (3M) 2.53M

EDIT metrics

81 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.58
Market cap
$396.24M

Price action

20 metrics
Price change (1W)
+5.5%
Price change (30D)
-8.8%
Price change (3M)
-10.7%
Price change (6M)
-21.8%
Price change (YTD)
+25.9%
Price change (1Y)
-37.7%
Trailing year
Price change (5Y)
-93.3%
52-week high
$4.14
52-week low
$1.67
Change from 52-week high
-37.7%
Change from 52-week low
+55.0%
Annualized volatility
82.1%
Annualized volatility (3M)
73.7%
Beta
2.3
RSI (14D)
47.8
Price vs SMA 50
-8.1%
Price vs SMA 200
-3.0%
Avg volume (3M)
2.53M
Relative volume
0.9
Average dollar volume
$7.13M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
153.58M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
5.1×
reciprocal yield 19.6%
EV / EBITDA
—
EV / EBIT
—
P / sales
8.4×
reciprocal yield 11.9%
P / book
3.8
reciprocal yield 26.6%
FCF yield
-30.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-18.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
3.4×
reciprocal yield 29.4%
EV / revenue historical average (5Y)
14.7×
reciprocal yield 6.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-05

Profitability

9 metrics
Gross margin
—
Operating margin
-161.4%
Trailing 12 months
Net margin
-157.3%
Gross profit (TTM)
—
Operating profit (TTM)
−$75.86M
Net income (TTM)
−$73.95M
Trailing 12 months
Diluted EPS (TTM)
$-0.66
FCF margin
-256.5%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.47
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.76
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.74
Operating cash flow per diluted share (TTM)
$-1.20
Free cash flow per diluted share (TTM)
$-1.21
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$0.85
Stock compensation per diluted share (TTM)
$0.09
Book value per share
$0.28

Growth

11 metrics
Revenue growth YoY
+232.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$47.01M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+41.3%
Year over year · more shares
Revenue CAGR (3Y)
+27.1%
Revenue CAGR (5Y)
-14.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-70.2%
Return on assets
-31.2%
Debt / equity
0.5
Current ratio
3.2
EBITDA (TTM)
—
Free cash flow (TTM)
−$120.55M
Quick ratio
3.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$155.91M
Latest balance sheet
Cash & equivalents
$181.81M
Total assets
$237.36M
Total debt
$55.74M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$119.86M
Capital expenditures (TTM)
$691,000
R&D (TTM)
$84.96M
SG&A (TTM)
—
Stock compensation (TTM)
$8.65M
R&D / revenue
180.7%
Stock compensation / revenue
18.4%

Ownership (13F)

9 metrics
13F filers
218
13F filer change QoQ
+8
Institutional ownership
78.7%
Conviction holders (share of 13F filers)
0.5%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+219.2%
Holder tenure
6.2
Price vs estimated holder cost
+12.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
10.3%

Short interest

3 metrics
Short interest
24.2%
Latest settlement · 9.4 days to cover
Days to cover
9.4d
Short-squeeze score
79 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$33,999
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1650664 CUSIP 28106W103 13F (30d) 25 filings 23 filers Visit website Investor relations